



(12) Translation of
European patent specification

(11) NO/EP 3421468 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
C07C 51/083 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.03.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.11.04
(86)	European Application Nr.	18164040.0
(86)	European Filing Date	2014.11.12
(87)	The European Application's Publication Date	2019.01.02
(30)	Priority	2013.11.13, US, 201361903893 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3068782, 2014.11.12
(73)	Proprietor	Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA
(72)	Inventor	TANOURY, Gerald J., 151 O'Malley Road, Marlborough, MA 01752, USA NUGENT, William, Aloysius, P.O. Box 1021, Manomet, MA 02345, USA DVORNIKOVS, Vadims, 45 Chace Hill Road, Lancaster, MA 01523, USA ROSE, Peter, Jamison, 4 Pine Brook Lane, Littleton, MA 01460, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge


(54)	Title	METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION
(56)	References Cited:	US-A- 4 349 552 JAESCHKE G ET AL: "HIGHLY ENANTIOSELECTIVE RING OPENING OF CYCLIC MESO-ANHYDRIDES TO ISOPROPYL HEMIESTERS WITH TI-TADDOLATES: AN ALTERNATIVE TO HYDROLYTIC ENZYMES?", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, 1 January 1998 (1998-01-01), pages 1190-1197, XP002444554, ISSN: 0022-3263, DOI: 10.1021/JO971731T KIM H S ET AL: "Heterogeneous organocatalysis for the asymmetric desymmetrization of meso-cyclic anhydrides using silica gel-supported bis-cinchona alkaloids", TETRAHE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 60, no. 52, 20 December 2004 (2004-12-20), pages 12051-12057, XP004768164, ISSN: 0040-4020, DOI: 10.1016/J.TET.2004.10.046 N. KHASELEV ET AL: "The role of the C-C double bond in alcohol elimination from MH+ ions of unsaturated bicyclic esters upon chemical ionization", JOURNAL OF MASS SPECTROMETRY, vol. 30, no. 11, 1 November 1995 (1995-11-01), pages 1533-1538, XP055160717, ISSN: 1076-5174, DOI: 10.1002/jms.1190301103

CONCEPTION NEMECEK ET AL: "Design of Potent IGF1-R Inhibitors Related to Bis-azaindoles", CHEMICAL BIOLOGY & DRUG DESIGN, vol. 76, no. 2, 9 August 2010 (2010-08-09) , pages 100-106, XP055127265, ISSN: 1747-0277, DOI: 10.1111/j.1747-0285.2010.00991.x

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


3421468

1


Patentkrav**1. Fremgangsmåte for fremstilling av Forbindelse (C)****(C)**

5 eller et farmasøytisk akseptabelt salt derav, hvori R¹ er etyl, omfattende:


(g) å omsette Forbindelse (A)

**(A)**

med kinin




10 og etylalkohol for å danne et addukt av kininet og Forbindelse (**C-1**)

**(C-1)**

(h) å bryte adduktet av kinin og Forbindelse (**C-1**) ved å behandle adduktet med HCl for å danne Forbindelse (**C-1**) eller et farmasøytisk akseptabelt salt derav; og

(i) å epimerisere Forbindelse (**C-1**) eller et farmasøytisk akseptabelt salt derav for å danne Forbindelse (C):

15

**(C)**

eller et farmasøytisk akseptabelt salt derav.

20

2. Fremgangsmåten ifølge krav 1, hvori epimeriseringstrinn (i) inkluderer å behandle forbindelse (C-1**) med et C₁₋₆-alkoksid.**

3421468

2

3. Fremgangsmåten ifølge krav 2, hvori C₁₋₆-alkoksidet omfatter *tert*-butoksid, *tert*-amylat eller hvilken som helst kombinasjon derav.

5